Search research articles
Contact Us
Filters
Showing results (71-80 of 84) with videos related to
Page
of 9
Sort By:
Journal of Neurosurgery
|
March 24, 2004
Efficacy of multiple intraarterial papaverine infusions for improvement in cerebral circulation time in patients with recurrent cerebral vasospasm
James K Liu, Michael S Tenner, Oren N Gottfried, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2016
Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines
Mithun Vinod Shah, Anne E Wiktor, Reid G Meyer, et al.
Cancer
|
September 15, 2020
Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study
Carlos E Vargas, Cameron S Thorpe, Amylou C Dueck, et al.
Journal of the National Cancer Institute
|
December 6, 2011
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria
Edith A Perez, Amylou C Dueck, Ann E McCullough, et al.
Cancer Research
|
May 20, 2016
Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain
Keith L Knutson, Raphael Clynes, Barath Shreeder, et al.
Journal of the National Cancer Institute
|
October 30, 2016
Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial
Edith A Perez, Karla V Ballman, Afshin Mashadi-Hossein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 7, 2025
Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Saranya Chumsri, Joseph J Larson, Emily Liu, et al.
Breast Cancer Research : BCR
|
June 15, 2018
Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer
Nadine Norton, Nicholas Fox, Christie-Ann McCarl, et al.
Breast Cancer Research and Treatment
|
April 14, 2021
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)
Tufia C Haddad, Jun He, Ciara C O'Sullivan, et al.
Breast Cancer Research and Treatment
|
March 13, 2013
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
Alvaro Moreno-Aspitia, Amylou C Dueck, Ismael Ghanem-Cañete, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 84) with videos related to
Sort By:
Page
of 9
Journal of Neurosurgery
|
March 24, 2004
Efficacy of multiple intraarterial papaverine infusions for improvement in cerebral circulation time in patients with recurrent cerebral vasospasm
James K Liu, Michael S Tenner, Oren N Gottfried, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2016
Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines
Mithun Vinod Shah, Anne E Wiktor, Reid G Meyer, et al.
Cancer
|
September 15, 2020
Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study
Carlos E Vargas, Cameron S Thorpe, Amylou C Dueck, et al.
Journal of the National Cancer Institute
|
December 6, 2011
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria
Edith A Perez, Amylou C Dueck, Ann E McCullough, et al.
Cancer Research
|
May 20, 2016
Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain
Keith L Knutson, Raphael Clynes, Barath Shreeder, et al.
Journal of the National Cancer Institute
|
October 30, 2016
Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial
Edith A Perez, Karla V Ballman, Afshin Mashadi-Hossein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 7, 2025
Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Saranya Chumsri, Joseph J Larson, Emily Liu, et al.
Breast Cancer Research : BCR
|
June 15, 2018
Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer
Nadine Norton, Nicholas Fox, Christie-Ann McCarl, et al.
Breast Cancer Research and Treatment
|
April 14, 2021
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)
Tufia C Haddad, Jun He, Ciara C O'Sullivan, et al.
Breast Cancer Research and Treatment
|
March 13, 2013
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
Alvaro Moreno-Aspitia, Amylou C Dueck, Ismael Ghanem-Cañete, et al.
Page
of 9